title: Old and new adjuvants for hepatitis B vaccines.
abstract: The safety and immunogenicity profiles of currently available recombinant hepatitis B vaccines are excellent. However, it remains a real challenge to induce protective immunity in the target groups that respond poorly or not at all to conventional vaccines. Ideally, a hepatitis B vaccine can be developed that conveys lifelong protection against infection rapidly after the injection of a single dose. Although this goal is far from being reached, important improvements have been made. Novel vaccine adjuvants have been developed that enhance the immunogenicity of recombinant hepatitis B vaccines while maintaining a good safety profile. The different adjuvants and adjuvant systems that are discussed herein have all been thoroughly evaluated in clinical trials and some have reached or are close to reach the market.
authors.affiliation: Centre for Vaccinology, Ghent University and University Hospital, De Pintelaan 185, 9000, Ghent, Belgium, geert.lerouxroels@ugent.be.
authors.forename: Geert
authors.initials: G
authors.lastname: Leroux-Roels
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic